169 results about "Herpes simplex disease" patented technology

The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 has fusogenic activity, and comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.

The present invention relates to a preparation method for a blattodea polypeptide substance, and a medical use of the blattodea polypeptide substance in anti-herpesvirus. Specifically the present invention relates to a blattodea extract effective fraction having a function of prevention and treatment of herpes simplex virus infection diseases, a preparation method and a medical use thereof. The Periplaneta Americana extract effective fraction of the present invention is a polypeptide substance with a molecular weight less than 5000 dalton, and is prepared by the following steps: carrying out extraction on fresh polypide or dried polypide of Periplaneta Americana with water or an organic solvent and a buffer, and then carrying out a membrane separation method to refine to obtain the product of the present invention, wherein the polypeptide active substance of the effective fraction has significant anti-herpes simplex virus (HSV-1 and HSV-2) activities, can be prepared into forms of a hydrogel, a cataplasm, lyophilized powder, a water agent, an aerosol, a suppository, a film agent, an external application liniment, and an ointment, and can be used for preparations of drugs for prevention and treatment of herpes simplex virus infections, daily chemical products or medical devices.

The invention relates to a method of treating neuronal apoptosis in a mammal using nucleic acid encoding HSV-2 ICP10PK, or a polypeptide encoded thereby. The invention further relates to a method of treating neuronal apoptosis in a mammal using ICP10PK in combination with a nucleic acid encoding bcl-2, or the polypeptide encoded thereby. The invention also relates to the use of ICP10PK and ICP10PK in combination with bcl-2 to treat non-neuronal diseases characterized by apoptosis.

The invention discloses a notoginsenoside ST-4 which is a new dammarane type triterpenoid saponin compound shown in the structural formula (I), and a preparation method thereof. The invention also provides applications of the notoginsenoside ST-4 in the preparation of drugs against HSV-1. An HSV-1 strain and HELF (MRC-5) are used as cell experimental subjects to carry out the experiment of antiviral activity of the new compound which is the notoginsenoside ST-4. The results show that the notoginsenoside ST-4 has therapeutical effect for cells infected by HSV-1 and can reduce the infectivity of HSV-1 for MRC-5 cells and be applied to the preparation of drugs against HSV-1.

The present invention provides a herpes virus in which a non-essential gene for replication is inactivated More particularly, the present invention provides a herpes virus in which a non-essential gene for replication present in a UL or US region is inactivated. More preferably, the non-essential gene for replication contains US3 or UL56. The herpes virus may be preferably a herpes simplex virus, and more preferably herpes simplex virus 1 or herpes simplex virus 2. The present invention provides a method, composition and use for treating various diseases or disorders including tumor and infectious diseases. The present invention also provides a method, composition and use for activating a prodrug.

The invention relates to an I, II herpes simplex virus fluorescence quantitative PCR detection method and kit thereof. Primers are designed direct towards DNA enzyme highly conservative region and then processed by PCR and a fluorescent probe is designed in the middle of the amplification sequence and then the annealing temperature of the reaction and the concentrations of the primers, the probe,the magnesium ion are optimized to establish the I, II herpes simplex virus real-time fluorescence PCR detection method. The kit ensures the sensitivity and accuracy and has features of simple and quick operation, reduced labor intensity of clinical detection, reduced cost of clinical PCR diagnosis, quick and simple performance of fluorescence quantitative PCR detection method. The method is usedfor quantitative detection of I, II herpes simplex virus with practical clinical application value.

The invention discloses a fluorescent polymerase chain reaction (PCR) kit for detecting herpes simplex virus type II, and belongs to the field of in-vitro diagnostic kit for nucleic acid. The kit comprises a positive reference, a negative reference, fluorescent polymerase chain reaction liquid, PCR primers and a specific fluorescent probe, polyethylene glycol (PEG) precipitation solution and lysis solution. The invention comprises a PCR system based on a fluorescent PCR technology, contains forward and reverse primers and the fluorescent probe for detecting the gene sequence of the herpes simplex virus type II, can detect the nucleotide sequence of the gene of the herpes simplex virus type II under proper PCR condition, can easily and quickly detect the infection of the HSV II in clinical samples and is high in specificity.

The invention provides recombined II-type herpes simplex virus. In the virus, ICP34.5 gene of a wild II-type herpes simplex virus HG52 strain is excluded, and a fluorescent protein expression box is inserted in the gene group. The invention also provides a preparation method of the recombined II-type herpes simplex virus, the application of the recombined II-type herpes simplex virus in preparation of the drug for diagnosing tumours, and a tumour diagnostic reagent kit with the recombined II-type herpes simplex virus. In the recombined II-type herpes simplex virus disclosed by the invention, the ICP34.5 gene is excluded, so that the recombined II-type herpes simplex virus can selectively grow and breed in tumour cells, the recombined II-type herpes simplex virus is inserted in the fluorescent protein expression box and can give out fluorescence in tumour cells, so that the tumour diagnostic reagent kit with the recombined II-type herpes simplex virus can quickly, accurately, sensitively and broadly detect whether a sample to be detected contains tumour cells or not.

The invention discloses a set of probes used for TORCH detection, and comprises a toxoplasma TOX probe which is shown in a SEQ ID NO. 1; a rubella virus RV probe which is shown in a SEQ ID NO.2; a cytomegalovirus CMV probe which is shown in a SEQ ID NO.3; a herpes simplex virus HSV I type probe which is shown in a SEQ ID NO.4; and a herpes simplex virus HSV II type probe which is shown in a SEQ ID NO.5. The invention also comprises a gene chip containing the probe and a kit thereof, visible light passing through a biochip can be amplified, signal resolution is high, and a signal can be shoot by a common digital camera or directly read by naked eyes. Compared with a traditional fluorescent label, the gene chip has good effect. Through specific primer and probe selection, by combining a gene chip technology, detection efficiency and accuracy degree are increased, and requirement of on-site detection for hospital and antenatal testing.

The invention provides methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. The protective immune response elicited by the methods and kits of the invention is characterized by robust humoral, cellular, and mucosal immunity. In particular, the invention provides a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.

The invention discloses a fluorescence quantitative polymerase chain reaction (PCR) kit for quickly detecting herpes simplex viruses (HSV) 2, which relates to technology for detecting pathogen genes causing a plurality of human diseases and is applied to the qualitative and quantitative detection of the herpes simplex viruses 2. The fluorescence quantitative PCR kit consists of DNA extracting solution, fluorescence quantitative PCR solution, an HSV2 standard positive temperature PMD18-T-HSV2 and a negative control standard, wherein the fluorescence quantitative PCR solution contains a herpes simplex virus 2-specific primer pair and a fluorescence probe. The fluorescence quantitative PCT kit ensures accurate quantization, high detection speed, high specificity and high sensitivity, and can highly-repeatedly and quickly qualitatively and quantitatively identify, distinguish and detect the herpes simplex viruses 2 by simple steps and replace conventional culture methods which are continuously used for long.

The invention relates to a pharmaceutical composition with dammarane-type tetracyclic triterpene compound as an active component and an application thereof to the pharmaceutical field. Panax notoginseng is separated to obtain three dammarane-type tetracyclic triterpene compounds as shown in the following structural formula, in vitro pharmacological experiments show that the pharmaceutical composition has good in vitro inhibitory activity for herpes simplex virus type I and can be applied to the preparation of medicines for resisting herpes simplex virus type I and is used for treating herpetic keratitis, encephalitis, pneumonia, ulcerative stomatitis, blister and the like caused by herpes simplex virus type I.

A method of treating patients having viral infections including herpes simplex virus 1 and 2 infections and human papillomavirus infections by topically administering Product R, a peptide-nucleic acid preparation, by itself or in a composition comprising Product R and other pharmaceutically acceptable carriers for topical administration, is disclosed.

The invention discloses a protein chip for detecting pathogen antibodies of blood and cerebrospinal fluid and its preparing method, and the protein chip includes substrate and peculiar-culture or shape protein or polypeptide antigen of array distributed pathogen and contrasted dot coating, where the substrate is a glass substrate; and the antigen and contrasted dot coating refers to 13 antigens with ten indexes including HSV-I, HSV-II, VZV, CMV, EBV, RV, JEV, MV, MT and LP, uniformly distributed on the glass substrate in a dot matrix form, and positive contrast, negative contrast and blank contrast. The protein chip of the invention can obtain multiple-index reacting result only by one reaction, judges infection of different pathogens and has the characters of quickness, high efficiency, accuracy and parallel diagnosis.

The present invention relates to an application of pithecellobium clypearia extract in medicine and food. It adopts pithecellobium clypearia aqueous extract or ethyl alcohol extract as effective component and adds conventional medicinal auxiliary or food additive, and can make them into tablet, capsul, granule preparation, pills preparation and oral liquor preparation. Said pithecellobium clypearia extract has strong inhibition effect for influenza virus, parainfluenza virus, enteric virus, rhinovirus and mumps virus and has strong antioxidation activity.

The invention provides a rubiaceae-type cyclopeptide compound rubiyunnanin F(8), a pharmaceutical composition with the compound as an active component, as well as a preparation method and application of the compound. The invention provides the preparation method of the compound and application of the compound in preparation of anti-herpes simplex virus type I (HSV-1) medicines.